Pradeep Kumar Vaitla, MD
Nephrology · Jackson, MSNPI 1255645446
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.5%), consulting fees and education — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by ZOLL Medical Corporation at 42.5% of the total. Reporting peaked in 2024 at $1,177 and has fallen 79.1% since, to $246 in 2025.
Across 19 payments — averaging $123.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Medical Corporation$1K
- Amgen$367
- Novartis$275
- United Therapeutics Corporation$133
- Veloxis Pharmaceuticals, Inc.$132
- AstraZeneca$99
- plus $346 from 5 others
What the payments were for
- Consulting fees$1,00043%
- Food & beverage$1,14049%
- Education$2119%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Medical Corporation | 1 | $1,000 |
| Amgen(2 entities) | 4 | $367 |
| Novartis | 2 | $275 |
| United Therapeutics Corporation | 1 | $133 |
| Veloxis Pharmaceuticals, Inc. | 2 | $132 |
| AstraZeneca | 1 | $99 |
| Aurinia Pharma U.S., Inc. | 1 | $89 |
| Merck | 4 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $79 |
| Mallinckrodt Enterprises LLC | 1 | $72 |
| Genentech, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Defibrillator$1,000
- EVENITY$206
- Prolia$206
- Fabhalta$135
- XGEVA$101
How this compares
$2,351 in reported general payments places this provider in the 60th percentile of 105 nephrology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LivtencityMaribavir | 22 | $524,078 |
| Cinacalcet Hcl | 272 | $58,840 |
| EliquisApixaban | 36 | $27,799 |
| Valganciclovir Hcl | 80 | $22,586 |
| LokelmaSodium Zirconium Cyclosilicate | 22 | $19,453 |
| Nifedipine ErNifedipine | 736 | $14,293 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $9,747 |
| EntrestoSacubitril/Valsartan | 13 | $8,393 |
| Tacrolimus | 72 | $6,786 |
| Mycophenolic AcidMycophenolate Sodium | 39 | $5,495 |
| Carvedilol | 758 | $3,594 |
| Potassium Citrate ErPotassium Citrate | 45 | $3,487 |
| Mycophenolate Mofetil | 44 | $3,195 |
| Prednisone | 738 | $3,154 |
| Hydralazine Hcl | 259 | $3,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Livtencity | $79 | $524,07822 claims |
| AstraZenecaLokelma | $99 | $19,45322 claims |
| NovartisEntresto | $275 | $8,39313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 105 nephrology providers in Mississippi.
Other nephrology in Jackson
- Ramzi VareldzisJackson$3K
- Murphy MartinJackson$3K
- James OnyirimbaJackson$2K
- Yoshitsugu ObiJackson$2K
- Carla MonicoJackson$2K
- Uma Mahesh AvulaJackson$1K
- Mohit AhujaFlowood$427K
- Padam HirachanNatchez$29K
- Brian RifkinHattiesburg$23K
- Otis GowdyMeridian$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.